Apeiron Investment Group is a discretionary investment firm and family office founded and owned by serial entrepreneur Christian Angermayer, managing approximately $7 billion. The firm invests across the entire company lifecycle — from incubation and seed to listed companies — with a focus on biotech & life sciences, fintech & crypto, deep tech, and experiences & hospitality.
37% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 2 prior). Average disclosed round size is $60.3M (across 13 rounds with reported amounts).
Portfolio
14
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
Jefim Gewiet
Managing Director
Nick Nigam
Partner & Chief Investment Officer
Vincent Wobbe
Partner
Christian Angermayer
Founder
Saskia Muelheim
Investments & Incubations
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Steven.com | Unknown | — | Oct 2025 |
 AtaiBeckley | Series C | $125M | Feb 2025 |
 Enhanced | Series B | — | Feb 2025 |
| AtaiBeckley | Series C | — | Jan 2025 |
| Enhanced | Seed | — | Jan 2024 |
| RRejuveron Life Sciences | Series B | $75M | Jan 2023 |
 TRIP | Unknown | $12M | Aug 2022 |
 Peek | Series C | $80M | Nov 2021 |
 Delix Therapeutics | Series A | $70M | Sep 2021 |
| OOlsam | Series A | — | Sep 2021 |
 Isar Aerospace Technologies GmbH | Series B | $75M | Jul 2021 |
 Blackrock Neurotech | Seed | $10M | May 2021 |
 Cambrian Biopharma | Unknown | $60M | Feb 2021 |
| Isar Aerospace Technologies GmbH | Series B | $91M | Dec 2020 |
| ZZenhomes | Series A | — | Aug 2019 |
| AtaiBeckley | Growth | $43M | — |
 Centenara Labs | Series B | $75M | — |
 AION | Pre-Seed | $25M | — |
| AtaiBeckley | Series B | $43M | — |
Top Co-Investors
Last updated: 20 October 2026